conjugated the EGFR-specific and FDA-approved mAb Panitumumab via NHS ester chemistry with IRDye 700Dx, generating Panitumumab-IR700, intending to create a targeted phototherapy, termed photoimmunotherapy (PIT) for bladder cancer (183). This evidence concerns the gene EGFR and urinary bladder carcinoma.